S&P 500
7,401.00
+0.91%
Dow Jones
49,665.70
+0.19%
Nasdaq 100
29,241.00
+2.43%
Russell 2000
2,860.88
+0.82%
FTSE 100
10,263.70
+0.48%
Nikkei 225
63,767.70
+2.68%

Health and Healthcare

Big Biotech: Best of 2010, Outlook in 2011 (ILMN, ITMN, INCY, THRX, VPHM, DNDN, AMGN, GILD, CELG, HGSI, ACOR)

Photo of Jon C. Ogg
By Jon C. Ogg Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
2010 is ending and 2011 is about to begin.  It has been a very interesting year for major biotech stocks, albeit with lower rewards than seen in 2009 as there have been far fewer ten-baggers with more than 1,000% gains in 2010.  Still, we have gone through a review of the “big biotechs” with a market cap cut off of $1 billion or higher.  What we found was a series of the big 2010 winners and we also found which of the big biotech players may have the most upside ahead in 2011.  Biohealth Investor has two separate groups reviewing those with the most implied upside for 2011 and also another showing those with best performance so far this year in 2010.

The big winners of 2010 have so far included shares of Illumina Inc. (NASDAQ: ILMN), InterMune Inc. (NASDAQ: ITMN), Incyte Corporation (NASDAQ: INCY), Theravance Inc. (NASDAQ: THRX), and ViroPharma Inc. (NASDAQ: VPHM). We have taken a look at what has driven the gains as well as what the prospects are for 2011 and beyond.  FULL REPORT

Dendreon Corporation (NASDAQ: DNDN) appears to have the most implied upside of the $1 billion and higher catgory, but others included are Amgen Inc. (NASDAQ: AMGN), Gilead Sciences, Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Human Genome Sciences, Inc. (NASDAQ: HGSI), Incyte Corporation (NASDAQ: INCY), and Acorda Therapeutics, Inc. (NASDAQ: ACOR).  The full list is available showing the implied upside and we have added color and commentary on each.  FULL REPORT

Stay tuned for many more sector updates in many sectors with winners of 2010 and the outlook for 2011 and beyond!

JON C. OGG

Photo of Jon C. Ogg
About the Author Jon C. Ogg →

Jon Ogg has been a financial news analyst since 1997. Mr. Ogg set up one of the first audio squawk box services for traders called TTN, which he sold in 2003. He has previously worked as a licensed broker to some of the top U.S. and E.U. financial institutions, managed capital, and has raised private capital at the seed and venture stage. He has lived in Copenhagen, Denmark, as well as New York and Chicago, and he now lives in Houston, Texas. Jon received a Bachelor of Business Administration in finance at University of Houston in 1992. www.247wallst.com.

Continue Reading

Jon C. Ogg |

Top Biotech Stock Picks For 2012 (ARIA, DNDN, GILD, HGSI, ILMN, INCY, JAZZ, LIFE, THRX, IBB, XBI)

The biotech sector has seen its share of ups and downs in 2011 and prior years.  It is almost always…

Jon C. Ogg |

Measuring Pre-Earnings Upside in Biotechs (DNDN, HGSI, GILD, AMLN, ARIA, INCY, IBB, XBI, BBH)

We have compiled a detailed list of expected upside in the biotech sector.  The sector has consolidated and now there…

Jon C. Ogg |

Nine Big Expected Biotech Winners for 2013 (ARIA, CBST, INCY, JAZZ, MDVN, ONXX, THRX, VPHM, VVUS)

Thinkstock24/7 Wall St. is looking for the next great biotech stocks for 2013 after great gains have been seen in…

Jon C. Ogg |

The Big Biotech Winners and Losers for 2013 (AMGN, BIIB, CELG, GILD, ALXN, ARIA, CBST, INCY, JAZZ, MDVN, ONXX, THRX, VPHM, VVUS)

ThinkstockBig biotech had a stellar 2012. In 2013, though, the large biotech companies may be dwarfed in performance by the…

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors
Jon C. Ogg |

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately,…

Jon C. Ogg |

The Least Attractive DJIA Stocks for 2011 (CAT, CVX, XOM, HD, IBM, VZ, T)

It’s already 2011 and we have our outlook pieces for the year for sectors and indexes.  While most of our…

Why Credit Suisse Sees Incyte Rising Over 15%
Chris Lange |

Why Credit Suisse Sees Incyte Rising Over 15%

Credit Suisse sees future earnings growth from Incyte’s pipeline, with epacadostat’s potential as a best-in-class immunotherapy combination agent making the…

Jon C. Ogg |

BioWatch: Biotechs With 50% Implied Upside (GENZ, CEPH, ALNY, DNDN, GERN, HALO, VVUS)

Biotech is about to become even less of a diversified sector due to mergers and acquisitions. Genzyme Corporation (NASDAQ: GENZ)…

Jon C. Ogg |

How Overvalued Are the Biggest Biotechs? (AMGN, BIIB, GILD, ALXN)

The largest biotech stocks have been great performers in 2012. The question is whether that can be sustained in 2013.…

Top Gaining Stocks

Akamai
AKAM • Vol: 21,556,944
Micron Technology
MU • Vol: 65,135,624
Intel
INTC • Vol: 227,504,426
Monster Beverage
MNST • Vol: 15,284,847
Dell Technologies
DELL • Vol: 12,167,525

Top Losing Stocks

Mettler Toledo International
MTD • Vol: 539,266
Motorola Solutions
MSI • Vol: 3,101,643
Expedia
EXPE • Vol: 4,189,786
Coterra Energy
CTRA • Vol: 73,319,495
Fidelity National Information Services
FIS • Vol: 11,468,820